Results 1 to 10 of about 1,614,566 (371)
Some of the next articles are maybe not open access.
Controllable Formation of (004)-Orientated Nb:TiO2 for High-Performance Transparent Conductive Oxide Thin Films with Tunable Near-Infrared Transmittance.
ACS Applied Materials and Interfaces, 2017 Xiaoyang Yang, Mingjian Zhang, Yuxin Min, Ming Xu, Zongwei Mei, Jun Liang, Jiangtao Hu, Sheng Yuan, S. Xiao, Y. Duan, Fusheng Liu, Hai Lin, Yuan Lin, F. Pan +13 moresemanticscholar +1 more sourceEfficacy of Prophylactic Low-Molecular Weight Heparin for Ambulatory Patients With Advanced Pancreatic Cancer: Outcomes From the CONKO-004 Trial.
Journal of Clinical Oncology, 2015 U. Pelzer, B. Opitz, G. Deutschinoff, M. Stauch, P. Reitzig, S. Hahnfeld, L. Müller, M. Grunewald, J. Stieler, M. Sinn, T. Denecke, S. Bischoff, H. Oettle, B. Dörken, H. Riess +14 moresemanticscholar +1 more sourceTolerability and Pharmacokinetics of SYN-004, an Orally Administered β-Lactamase for the Prevention of Clostridium difficile-Associated Disease and Antibiotic-Associated Diarrhea, in Two Phase 1 Studies
Clinical drug investigation, 2016 Tracey E. Roberts, J. Kokai-Kun, Olivia Coughlin, Barbara Valero Lopez, Heidi Whalen, J. Bristol, S. Hubert, J. Longstreth, K. Lasseter, Joseph A. Sliman +9 moresemanticscholar +1 more sourceIncidence and predictors of restenosis after coronary stenting in 10 004 patients with surveillance angiography
Heart, 2013 S. Cassese, R. Byrne, T. Tada, S. Pinieck, M. Joner, T. Ibrahim, Lamin A. King, M. Fusaro, K. Laugwitz, A. Kastrati +9 moresemanticscholar +1 more sourceImmunogenicity of Elosulfase Alfa, an Enzyme Replacement Therapy in Patients With Morquio A Syndrome: Results From MOR-004, a Phase III Trial.
Clinical Therapeutics, 2015 B. Schweighardt, T. Tompkins, Kelly Lau, L. Jesaitis, Yulan Qi, D. Musson, Pamela Farmer, C. Haller, A. Shaywitz, Ke Yang, C. O’Neill +10 moresemanticscholar +1 more source